NASDAQ:ATHE Alterity Therapeutics H1 2026 Earnings Report $4.88 -0.11 (-2.11%) As of 11:43 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Alterity Therapeutics EPS ResultsActual EPS-$0.18Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAlterity Therapeutics Revenue ResultsActual Revenue$0.93 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAlterity Therapeutics Announcement DetailsQuarterH1 2026Date1/31/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsAlterity Therapeutics' Q4 2026 TU earnings is estimated for Friday, August 28, 2026, based on past reporting schedulesConference Call ResourcesInterim ReportEarnings HistoryCompany ProfilePowered by Earnings DocumentsInterim report Alterity Therapeutics Earnings HeadlinesAlterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026July 21 at 7:25 AM | globenewswire.comAlterity Therapeutics Corporate Event Calendar | NASDAQ:ATHEJuly 18, 2026 | benzinga.comHe bet half his $9 billion on ONE stockOne of the most successful fund managers of the past 50 years put more than $4.5 billion - over half his fund - into a single, little-known company. His firm then bought more shares for 61 straight trading days, and the former CEO of Google soon struck a nine-figure partnership with the same company. This company controls nearly a million acres of scarce, irreplaceable minerals now protected by a White House executive order signed January 14, 2026. It has already outperformed Apple, Amazon, and the S-P 500 combined - and Whitney Tilson believes the biggest gains are still ahead.July 22 at 1:00 AM | Stansberry Research (Ad)Alterity Therapeutics Secures FDA-Confirmed Registrational Pathway for ATH434 in Multiple System AtrophyJuly 10, 2026 | theglobeandmail.comAnalysts Are Bullish on These Healthcare Stocks: Alterity Therapeutics (ATHE), Vera Therapeutics (VERA)July 9, 2026 | theglobeandmail.comALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System AtrophyJuly 7, 2026 | finanznachrichten.deSee More Alterity Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alterity Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alterity Therapeutics and other key companies, straight to your email. Email Address About Alterity TherapeuticsAlterity Therapeutics (NASDAQ:ATHE) is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation. Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials. Another key program, PBT434, is an oral small molecule aimed at modulating metal-mediated oxidative stress, currently in early-stage development for Parkinson’s disease and related disorders. Originally established in 1998 as Neuren Pharmaceuticals, the company rebranded to Alterity Therapeutics in 2023 to reflect its distinct focus on neurodegenerative conditions. Headquartered in Australia, Alterity conducts global clinical studies across North America, Europe and Australia, leveraging strategic partnerships to advance its pipeline toward regulatory milestones.View Alterity Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Apple Could Be the Last One Standing in the Tech Wreck3M's Redemption Arc: Can Q2 Earnings Change the Narrative?Texas Power Play: Hut 8 Sparks a $9.8B AI Infrastructure DealAlphabet Is Planning a New AI Chip. Here's Why It Matters Ahead of EarningsConfidence Is Back, But Earnings Show the Consumer Is Being PickyIndustrial and Utility Giants Boost Dividends as Data Center Tailwinds BuildPayPal Rejected a $53 Billion Takeover Bid: Is the Stock Undervalued? Upcoming Earnings RTX (7/23/2026)Lockheed Martin (7/23/2026)Newmont (7/23/2026)Intel (7/23/2026)Nokia (7/23/2026)Relx (7/23/2026)SAP (7/23/2026)STMicroelectronics (7/23/2026)T-Mobile US (7/23/2026)Comfort Systems USA (7/23/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
